What is Cromatic?
Founded in 2022, Cromatic operates a sophisticated cloud-based digital marketplace designed to optimize the R&D process for biotech firms. The platform serves as a centralized hub for identifying, vetting, and managing Contract Research Organizations (CROs). By providing an intuitive interface for project outsourcing, Cromatic addresses critical inefficiencies in the drug discovery and development pipeline.
The company's value proposition lies in its integrated task management software, which facilitates seamless communication and milestone tracking between sponsors and service providers. This end-to-end management capability allows biotech companies to maintain rigorous oversight of their research projects, from initial inception to final delivery, thereby reducing operational friction and accelerating time-to-market for critical innovations.
How much funding has Cromatic raised?
Cromatic has raised a total of $5.3M across 1 funding round:
Other Financing Round
$5.3M
Other Financing Round (2023): $5.3M with participation from AgFunder, What If Capital, WorkLife Ventures, and FJ Labs
Key Investors in Cromatic
AgFunder
A global venture capital firm focused on advancing agrifood and planetary health through investments in deeptech platforms, including AI and biotech.
What If Capital
An investment firm specializing in mental health and disruptive healthcare technologies, providing both capital and an 8-week accelerator program.
WorkLife Ventures
A venture capital firm focused on the future of work, backing technical teams and creators with a network supported by founders of major tech platforms.
What's next for Cromatic?
With the support of its latest capital injection, Cromatic is poised to deepen its market penetration and enhance its platform capabilities. The strategic focus will likely shift toward scaling its user base and refining its algorithmic matching engine to better connect biotech sponsors with specialized CROs. As the industry continues to embrace digital transformation, Cromatic is strategically positioned to become the standard operating system for outsourced life sciences research.
Future growth initiatives will likely involve expanding the platform's feature set to include more advanced analytics and compliance tools, further cementing its role as an essential partner for biotech R&D teams. By leveraging its current momentum, the company aims to bridge the gap between complex research requirements and efficient execution, ultimately driving higher productivity across the global biotech ecosystem.
